Development of investigational radiation modifiers.
National Cancer Institute, Bethesda, MD, USA. colevasd@ctep.nci.nih.gov
A Dimitrios
AD
Colevas
J Martin
JM
Brown
Stephen
S
Hahn
James
J
Mitchell
Kevin
K
Camphausen
C Norman
CN
Coleman
D004999:Amifostine / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D019091:Critical Pathways; D015507:Drugs, Investigational / Q000494:pharmacology; D006801:Humans; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000532:radiotherapy; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology; D012107:Research Design; D014481:United States
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D011838:Radiation-Sensitizing Agents; D004999:Amifostine